Figure S3 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Year: 2023
Type: other
Abstract: Multispectral staining of the immune cell infiltrate in melanoma. A, Low power magnification depicting marked variability in the immune cell types. B, Higher magnification showing PDL1 expression on melanoma cells (arrow) and multiple m-MDSCs in contact with melanoma and CD8+ T cells. C, PD-L1 expressing melanoma cells (arrows) are infiltrated by PMN-MDSCs, regulatory T cells, CD4+ T helper cells and CD8+ cytotoxic T cells. D, PD-L1 negative melanoma with CD8+ cytotoxic T cells, T helper cells and m-MDSCs.
Authors: Shipra Gandhi, Manu R. Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, Marc S. Ernstoff
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362411409